Iovance Biotherapeutics (IOVA) Resumen de Acciones
Iovance Biotherapeutics, Inc, una empresa biofarmacéutica en fase comercial, desarrolla y comercializa terapias celulares que utilizan linfocitos autólogos infiltrados en tumores para el tratamiento del melanoma metastásico y otros cánceres de tumores sólidos en Estados Unidos y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 5/6 |
| Crecimiento futuro | 5/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 5/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
IOVA Community Fair Values
Create NarrativeSee what 142 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Iovance Biotherapeutics, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$4.08 |
| Máximo en las últimas 52 semanas | US$5.63 |
| Mínimo de 52 semanas | US$1.66 |
| Beta | 0.70 |
| Cambio en 1 mes | 18.26% |
| Variación en 3 meses | 0.99% |
| Cambio de 1 año | 82.14% |
| Variación en 3 años | -49.75% |
| Variación en 5 años | -83.54% |
| Variación desde la OPV | -21.66% |
Noticias y actualizaciones recientes
Seeking Alpha • Jun 10
Iovance Biotherapeutics: Progress With Caveats
Summary Iovance Biotherapeutics (IOVA) faces execution issues post-Amtagvi approval, with FY25 sales significantly lower than initial guidance and significant share dilution. IOVA’s TIL therapy Amtagvi is the first FDA-approved individualized T-cell therapy for solid tumors, with ongoing trials in melanoma, NSCLC, and other indications. Despite a low gross margin (41–50%) and aggressive ATM share issuance, IOVA maintains a cash runway into 2028 and trades at 2.2x FY28E sales. Given recent execution shortfalls, IOVA is now a ‘show-me’ stock, best suited for covered call strategies as it hopefully grinds higher from current levels. Read the full article on Seeking Alpha
Actualización de narrativa • Jun 03
IOVA: Competitive Setbacks And New IL 12 Program Will Support Higher Future P/E
Analysts have modestly adjusted their outlook on Iovance Biotherapeutics, with recent price target changes including UBS moving to $4 from $2 and Chardan trimming its target by $2. These revisions reflect mixed views on fundamentals, the pace of Amtagvi uptake, and potential benefits from a competing product setback.Actualización de narrativa • May 14
IOVA: Margin Gains And 2026 Sarcoma Readouts Will Support Higher Future P/E
Analysts have trimmed the fair value estimate for Iovance Biotherapeutics to $14.00 from $16.00, reflecting updated views on revenue growth potential, margin trajectory, and a higher future P/E multiple, following recent research highlighting both Q4 operational progress and ongoing uncertainties around Amtagvi acceleration. Analyst Commentary Recent Street research shows a mixed but generally constructive tone around Iovance Biotherapeutics, with several bullish analysts highlighting improving execution in Q4, progress on margins, and potential benefits from external events in the competitive set.Artículo de análisis • May 11
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) missed earnings with its latest first-quarter results, disappointing...Recent updates
Seeking Alpha • Jun 10
Iovance Biotherapeutics: Progress With Caveats
Summary Iovance Biotherapeutics (IOVA) faces execution issues post-Amtagvi approval, with FY25 sales significantly lower than initial guidance and significant share dilution. IOVA’s TIL therapy Amtagvi is the first FDA-approved individualized T-cell therapy for solid tumors, with ongoing trials in melanoma, NSCLC, and other indications. Despite a low gross margin (41–50%) and aggressive ATM share issuance, IOVA maintains a cash runway into 2028 and trades at 2.2x FY28E sales. Given recent execution shortfalls, IOVA is now a ‘show-me’ stock, best suited for covered call strategies as it hopefully grinds higher from current levels. Read the full article on Seeking AlphaActualización de narrativa • Jun 03
IOVA: Competitive Setbacks And New IL 12 Program Will Support Higher Future P/E
Analysts have modestly adjusted their outlook on Iovance Biotherapeutics, with recent price target changes including UBS moving to $4 from $2 and Chardan trimming its target by $2. These revisions reflect mixed views on fundamentals, the pace of Amtagvi uptake, and potential benefits from a competing product setback.Actualización de narrativa • May 14
IOVA: Margin Gains And 2026 Sarcoma Readouts Will Support Higher Future P/E
Analysts have trimmed the fair value estimate for Iovance Biotherapeutics to $14.00 from $16.00, reflecting updated views on revenue growth potential, margin trajectory, and a higher future P/E multiple, following recent research highlighting both Q4 operational progress and ongoing uncertainties around Amtagvi acceleration. Analyst Commentary Recent Street research shows a mixed but generally constructive tone around Iovance Biotherapeutics, with several bullish analysts highlighting improving execution in Q4, progress on margins, and potential benefits from external events in the competitive set.Artículo de análisis • May 11
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) missed earnings with its latest first-quarter results, disappointing...
Actualización de narrativa • Apr 29
IOVA: Q4 Margin Progress And Sarcoma Data Will Drive Upside Potential
Narrative Update: Iovance Biotherapeutics The analyst price target for Iovance Biotherapeutics has been lifted to $4. This reflects updated models that incorporate Q4 fundamentals, margin progress and expectations around Amtagvi and broader trial momentum, while still acknowledging areas of uncertainty highlighted by recent Street research.Actualización de narrativa • Apr 14
IOVA: Q4 Margin Gains And Sarcoma Data Are Expected To Drive Upside
The average analyst price target for Iovance Biotherapeutics has moved higher toward $4, supported by research citing improved Q4 fundamentals, margin progress, and early signs that initial launch issues may be easing. Analyst Commentary Recent research highlights a mix of optimism around product execution and margins alongside pockets of caution on valuation and growth risks.Actualización de narrativa • Mar 31
IOVA: Margin Progress And 2026 Sarcoma Data Outlook Will Support Higher Future P/E
The analyst fair value estimate for Iovance Biotherapeutics has been adjusted from $17.00 to $16.00, reflecting updated views on revenue growth, margins, and future P/E assumptions as analysts respond to recent price target moves and Q4 results across the Street. Analyst Commentary Street research around the latest quarter points to a generally constructive shift in sentiment, with several bullish analysts lifting price targets and, in one case, upgrading the rating on Iovance Biotherapeutics.Actualización de narrativa • Mar 16
IOVA: Fair Outlook Balances Q4 Progress With 2026 Clinical And Launch Risks
The analyst price target for Iovance Biotherapeutics has shifted from $2 to $4 as analysts point to stronger Q4 fundamentals, improving margins, ongoing manufacturing progress, and early signs that some initial launch issues for Amtagvi may be easing, even while longer term revenue acceleration remains uncertain. Analyst Commentary Recent Street research around Iovance Biotherapeutics reflects a mixed setup, with price target changes clustered across a wide range and ratings spanning Neutral to Buy.Actualización de narrativa • Mar 02
IOVA: Elevated Future P/E Will Likely Clash With 2026 Clinical Data Risks
Analysts have lifted their price targets on Iovance Biotherapeutics from a range starting at $3 to as high as $16, citing Q4 revenue momentum, improving gross margins and manufacturing efficiency, and expectations for more clinical data in 2026. Analyst Commentary Recent research highlights a split in how Wall Street views Iovance Biotherapeutics, with some firms lifting price targets on the back of Q4 execution and others trimming expectations while still acknowledging operational progress.Actualización de narrativa • Feb 16
IOVA: Elevated Future P/E Will Likely Expose Execution Risk
Analysts have raised their price target on Iovance Biotherapeutics by $0.50, citing updated assumptions around fair value, growth, margins, and future P/E that reflect recent Street research. Analyst Commentary Recent Street research on Iovance Biotherapeutics has highlighted a mix of optimism and caution around the updated price target, with some readers likely to focus less on the small US$0.50 change and more on what it implies about risk and execution.Actualización de narrativa • Feb 02
IOVA: Reaffirmed 2025 Revenue Outlook Will Support A Higher Future P/E
Analysts have trimmed their fair value estimate for Iovance Biotherapeutics from US$20.00 to US$17.00, citing updated assumptions that include a slightly higher discount rate, a lower projected revenue growth rate, a modestly higher profit margin, and a reduced future P/E multiple. What's in the News Iovance Biotherapeutics reaffirmed its full year 2025 revenue guidance, keeping the expected range at US$250 million to US$300 million for the first full calendar year of Amtagvi sales (Key Developments).
Actualización de narrativa • Jan 19
IOVA: Lung Cancer Trial Progress Will Drive Bullish Repricing Ahead
Analysts have kept their price target for Iovance Biotherapeutics steady at US$8.35, citing only minor tweaks to inputs such as the discount rate and long term P/E assumptions rather than any fundamental shift in their outlook. What's in the News Iovance Biotherapeutics reaffirmed its full year 2025 revenue guidance, keeping the range at US$250 million to US$300 million for the first full calendar year of Amtagvi sales (Company guidance).Actualización de narrativa • Jan 05
IOVA: Future Lung Cancer Data Will Drive Renewed Bullish Momentum
Analysts have modestly increased their price target on Iovance Biotherapeutics by 0.10 dollars to reflect slightly lower perceived risk, as seen in a reduced discount rate, while maintaining robust long term revenue growth and profit margin expectations alongside a marginally higher future price to earnings multiple. What's in the News Iovance reaffirmed its full year 2025 revenue guidance of 250 to 300 million dollars for the first full calendar year of Amtagvi sales, signaling confidence in launch momentum (company guidance) Interim data from the registrational Phase 2 IOV-LUN-202 trial showed a 25.6 percent objective response rate for lifileucel monotherapy in previously treated advanced nonsquamous NSCLC without actionable mutations, including 2 complete and 7 partial responses and a 71.8 percent disease control rate (company trial update) The median duration of response for lifileucel in IOV-LUN-202 has not yet been reached after a median follow up of 25.4 months, indicating durable benefit among responding NSCLC patients (company trial update) Valuation Changes Fair Value: increased slightly from 8.25 dollars to 8.35 dollars, reflecting a modest uplift in the intrinsic valuation estimate.Actualización de narrativa • Dec 15
IOVA: Future Lung Cancer Data Will Drive Renewed Bullish Momentum
Analysts have modestly reduced their price target on Iovance Biotherapeutics to reflect slightly slower projected revenue growth, a meaningfully lower long term profit margin outlook, and a higher assumed future price to earnings multiple, while leaving the estimated fair value effectively unchanged at about 8.25 dollars per share. What's in the News Iovance Biotherapeutics reaffirmed its full year 2025 revenue guidance, targeting between 250 million dollars and 300 million dollars in the first full calendar year of Amtagvi sales (company guidance).Actualización de narrativa • Nov 30
IOVA: Future Phase 2 Data Will Drive Renewed Bullish Momentum
Analysts have raised their price target for Iovance Biotherapeutics from $7.75 to $8.25 per share, citing updated financial metrics and modestly adjusted long-term growth assumptions. What's in the News Iovance Biotherapeutics reaffirmed its revenue guidance for the full year 2025, projecting $250 to $300 million in the first full calendar year of Amtagvi sales.Actualización de narrativa • Nov 16
IOVA: Future Profitability Outlook Will Drive Renewed Investor Interest
Analysts have adjusted their price target for Iovance Biotherapeutics from $8.00 to $7.75. This change reflects updated views on the company's growth trajectory and profitability outlook.Artículo de análisis • Nov 08
Here's What Analysts Are Forecasting For Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) After Its Third-Quarter Results
Shareholders of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) will be pleased this week, given that the stock price is...Actualización de narrativa • Nov 02
IOVA: Advanced Melanoma Approval and Equity Raise Will Drive Upside Potential
Analysts have lowered their price target for Iovance Biotherapeutics from $9.10 to $8.00. They cite updated expectations for slower revenue growth, compressed profit margins, and a higher required rate of return.Actualización de narrativa • Aug 25
Oncology Expansion And Global Approvals Will Unlock Future Markets
The consensus analyst price target for Iovance Biotherapeutics has been revised downward to $9.10 as slower-than-expected Amtagvi commercial adoption and logistical challenges outweigh positive early clinical response data. Analyst Commentary Bearish analysts cite a slower-than-expected commercial launch for Amtagvi in second-line melanoma, driving down sentiment and price targets.Actualización de narrativa • Aug 10
Oncology Expansion And Global Approvals Will Unlock Future Markets
The decrease in Iovance Biotherapeutics' consensus price target is primarily driven by a reduction in expected annual revenue growth from 49.7% to 45.5%, resulting in a lowered fair value estimate from $10.00 to $9.10. What's in the News Five-year results from the Phase 2 C-144-01 trial showed Amtagvi (lifileucel) produced a median OS of 13.9 months and a 31.4% objective response rate in advanced melanoma patients; 19.7% survived at five years with durable responses and no new safety concerns.Artículo de análisis • Jul 22
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) shareholders are no doubt pleased to see that the share price has bounced...Artículo de análisis • May 16
Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) 46% Dip In Price Shows Sentiment Is Matching Revenues
Unfortunately for some shareholders, the Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) share price has dived 46% in the...Artículo de análisis • May 13
News Flash: 12 Analysts Think Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Earnings Are Under Threat
The analysts covering Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) delivered a dose of negativity to shareholders...
Nueva narrativa • Apr 22
US Launch And Global Expansion Will Create New Opportunities
The U.S. launch of Amtagvi and international expansion could drive significant revenue and market growth, enhancing revenue streams and market share.Seeking Alpha • Apr 22
Iovance Biotherapeutics: Only For The Brave
Summary Shares of Iovance Biotherapeutics have plummeted post-Amtagvi approval due to excessive ATM usage and 7% shareholder dilution, despite solid financials and reaffirmed FY25 outlook. Iovance's TIL therapy, Amtagvi, is FDA-approved for advanced melanoma and is in trials for other oncology indications, including NSCLC and endometrial cancer. Despite significant cash burn and unprofitability until at least FY27, Iovance's extensive trials and potential blockbuster status for Amtagvi present multi-bagger potential. An analysis around Iovance Biotherapeutics follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Mar 18
Iovance: The Company Makes It Hard To Estimate Revenue Growth
Summary Iovance reported Q4'24 revenues of $25M from Proleukin, a 51% increase from the prior quarter, but Amtagvi revenues of 48.7M, were up just 16% from the prior quarter. Proleukin revenues could be a leading indicator for Amtagvi revenues, but the company also supplied a new distributor in Q4'24, making it hard to judge Q1'25 Amtagvi growth. Obsidian Therapeutics represents a relevant competitor with a cell therapy called OBX-115, that has potential advantages over lifileucel, although IOVA has its own next-gen therapies in development. Read the full article on Seeking AlphaArtículo de análisis • Mar 02
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported Earnings, And Analysts Cut Their Target Price
There's been a major selloff in Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) shares in the week since it released its...Seeking Alpha • Feb 28
Iovance's Q4: Execution Risks Mount As Infusion Growth Slows (Rating Downgrade)
Summary Iovance Biotherapeutics, Inc.'s valuation has halved since August; Amtagvi, its FDA-approved TIL therapy, generated $12.8M in initial revenue, but faces significant risks. Q3 and Q4 performances showed mixed results, with $42.1M and $48.7M in Amtagvi revenues, respectively, and a notable cash burn. Despite high costs and competition, Amtagvi remains a preferred option in PD-1-refractory melanoma, with plans to increase its price for better margins. Given the complex and costly nature of TIL therapy, I downgrade IOVA stock to “hold,” acknowledging both its potential and significant risks. Read the full article on Seeking AlphaArtículo de análisis • Jan 11
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) May Have Run Too Fast Too Soon With Recent 25% Price Plummet
To the annoyance of some shareholders, Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) shares are down a considerable 25...Seeking Alpha • Dec 17
Iovance Biotherapeutics: Amtagvi Launch Growing, But Stock Isn't
Summary Iovance's guidance for FY2025 is for total product revenues of $450M-$475M, reflecting confidence in Amtagvi's strong market launch. Preliminary Q4'24 numbers on patient infusions could be considered to reflect a slowing rate of growth, albeit still growth, or just some seasonality, among other possibilities. IOVA can nonetheless meet its FY2025 guidance, although timely approval ex-US of Amtagvi will likely be required, with UK approval in H1'25 and EU approval in H2'25 possible. Read the full article on Seeking AlphaSeeking Alpha • Nov 11
Iovance Biotherapeutics Q3: A Beat, But A Selloff - Now A Buy Opportunity
Summary Iovance Biotherapeutics' Q3 earnings outperformed expectations, with $58.6m in revenue, but shares fell due to high market expectations and competition concerns. Amtagvi, Iovance's lead drug, shows strong commercial potential with 2025 revenue guidance of $450-$475m and significant opportunities in melanoma and other cancers including NSCLC. Despite high cash burn and competition, Iovance's growth in revenue, reimbursement, and treatment centers suggests a “buy the dip” opportunity for risk-tolerant investors. The company is progressing towards profitability, with promising pipeline developments and potential 25-40% IOVA stock price growth over the next 12 months. Read the full article on Seeking AlphaSeeking Alpha • Oct 03
Iovance Biotherapeutics: Moving To The Next Phase
Summary Iovance Biotherapeutics' Amtagvi has gained rapid market traction post-FDA approval, with strong Q3 performance and promising revenue projections for 2024 and beyond. The company's growth prospects are bolstered by potential regulatory approvals in international markets and ongoing trials in other cancer types, including NSCLC. Despite the positive outlook, risks include market penetration challenges, regulatory hurdles, competition, and financial sustainability concerns due to ongoing cash burn. I am looking to add to my IOVA position at current valuations, anticipating a potential reversal and long-term growth. Read the full article on Seeking AlphaSeeking Alpha • Sep 06
Iovance Therapeutics: Historic Product, Tough Commercial Outlook
Summary Iovance's cell therapy Amtagvi has received an historic FDA approval for treating unresectable or metastatic melanoma, but its stock has fallen over 70% since 2020. Despite first revenues from Amtagvi and Proleukin in Q2, financial uncertainties and a high cash burn raise concerns about Iovance's long-term profitability and market viability. Management's lack of detailed revenue breakdown and challenges with insurance approvals and competition create a little uncertainty around Amtagvi's commercial success. While promising label expansions and full approval could boost prospects, current financial, regulatory, and commercial uncertainties justify maintaining a "Hold" rating. Read the full article on Seeking AlphaArtículo de análisis • Aug 11
Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) just released its quarterly report and things are looking bullish...Seeking Alpha • Aug 11
Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)
Summary Iovance's Q2 2024 revenue of $31.1 million surpassed analyst expectations. Amtagvi, Iovance's TIL therapy, generated $12.8 million in its first full quarter post-approval. Iovance's ongoing trials in NSCLC and endometrial cancer could expand lifileucel's market potential. The company projects $160–$165 million in full-year 2024 revenue, with substantial growth expected by 2025. I am upgrading Iovance stock to a "buy" based on the improved outlook for Amtagvi and potential revenue growth. Read the full article on Seeking AlphaSeeking Alpha • Jun 26
Iovance Biotherapeutics: Amtagvi Launch Continues Upward
Summary The Amtagvi launch has seen over 100 patients enrolled for therapy since approval, with potential for Q2'24 earnings to reflect some initial sales. IOVA's enrollment of the TILVANCE-301 continues, with updates on enrollment serving as a potential catalyst. Key cohorts of a study of lifileucel in non-small cell lung cancer are set to complete enrollment in 2025. Read the full article on Seeking AlphaSeeking Alpha • May 10
Iovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagvi
Summary Iovance Biotherapeutics reported its Q1 2024 earnings yesterday. The company made a net loss of $(113m), or $(0.42) per share. Iovance secured a historic approval for a first solid tumor targeting cell therapy in mid-Feb, triggering overnight gains of close to 100%. Now, the market is turning its attention to revenue figures and patient enrollment for Amtagvi, approved to treat melanoma. Yesterday's updates provided by management seemed upbeat, but analysts had many questions and the share price has been falling today. In this post, I provide a thorough overview of the state of play post Q1 '24 earnings, and speculate on key themes that will dictate IOVA stock price movements going forward. Read the full article on Seeking AlphaSeeking Alpha • Apr 09
Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results
Summary Iovance Biotherapeutics is experiencing a favorable moment following FDA approval for its melanoma drug Amtagvi and a successful underwritten offering. The company has developed its own production capacity and aims to become a global leader in TIL therapies for cancer patients. Insider ownership has increased by over 50%, indicating strong confidence in the company's future results. Read the full article on Seeking AlphaSeeking Alpha • Mar 25
Iovance Biotherapeutics: Initial Amtagvi Launch In Focus
Summary Iovance's tumor-infiltrating lymphocyte (TIL) product, Amtagvi, was recently approved by the FDA for the treatment of advanced melanoma patients who have failed a PD-1 blocking antibody. Initial numbers from the early days of the launch can be considered when trying to project revenues from Amtagvi going forward. IOVA can improve potential revenues by gaining approval of its TIL therapies like Amtagvi outside of the US and in new indications. In the short term, however, the focus may be on the current Amtagvi launch, where some success may already be reflected in the price. Read the full article on Seeking AlphaSeeking Alpha • Feb 20
Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma
Summary Iovance Biotherapeutics' stock has increased over 50% since September, following positive news about its TIL therapy for advanced melanoma. The FDA has granted approval for Iovance's TIL therapy, named Amtagvi, for the treatment of advanced melanoma after anti-PD-1 and targeted therapy. Amtagvi has the potential to carve out a niche in the crowded melanoma treatment market, offering hope to patients with few options left. Read the full article on Seeking AlphaSeeking Alpha • Jan 19
Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date
Summary Iovance Biotherapeutics is preparing for the extended FDA deadline to determine the approval of lifileucel for advanced melanoma treatment. The FDA has put a clinical hold on the company's Phase II study for LN-145, which has raised concerns about the approval of lifileucel. Iovance has the capacity and preparations for a successful launch of lifileucel in the US, with plans for a potential approval in Europe. Read the full article on Seeking AlphaRentabilidad de los accionistas
| IOVA | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | -3.5% | 1.7% | 0.5% |
| 1Y | 82.1% | 27.8% | 23.5% |
Rentabilidad vs. Industria: IOVA superó a la industria US Biotechs, que obtuvo un rendimiento del 27.8% el año pasado.
Rentabilidad vs. Mercado: IOVA superó al mercado US, que obtuvo un rendimiento del 23.5% el año pasado.
Volatilidad de los precios
| IOVA volatility | |
|---|---|
| IOVA Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: El precio de las acciones de IOVA ha sido volátil durante los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de IOVA(12%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2007 | 975 | Frederick Vogt | www.iovance.com |
Iovance Biotherapeutics, Inc, una empresa biofarmacéutica en fase comercial, desarrolla y comercializa terapias celulares que utilizan linfocitos autólogos infiltrantes de tumores para el tratamiento del melanoma metastásico y otros cánceres de tumores sólidos en Estados Unidos y a escala internacional. La empresa ofrece Amtagvi, una terapia individualizada con células T para el cáncer de tumor sólido y para el tratamiento de pacientes adultos con melanoma avanzado, irresecable o metastásico previamente tratado; y Proleukin, un producto de interleucina-2 para el tratamiento de pacientes con melanoma metastásico y carcinoma metastásico de células renales. También desarrolla lifileucel para el tratamiento del melanoma, el cáncer de cuello uterino, el cáncer de pulmón no microcítico (CPNM), el cáncer de endometrio y el carcinoma de células escamosas de cabeza y cuello (CECC); LN-145-S1 para tratar el melanoma y el CECC; LN-145 Gen 3 y core biopsy para el tratamiento del CPNM; LN-145 Gen 3 para tratar el melanoma y el HNSCC; IOV-2001 para tratar la leucemia linfocítica crónica y el linfoma linfocítico pequeño; IOV-4001 para el tratamiento del melanoma y el NSCLC; e IOV-3001 para su uso en el régimen de tratamiento de la terapia TIL.
Resumen de fundamentos de Iovance Biotherapeutics, Inc.
| Estadísticas fundamentales de IOVA | |
|---|---|
| Capitalización bursátil | US$1.82b |
| Beneficios(TTM) | -US$353.86m |
| Ingresos (TTM) | US$285.61m |
6.4x
Ratio precio-ventas (PS)-5.1x
Ratio precio-beneficio (PE)¿Está IOVA sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de IOVA | |
|---|---|
| Ingresos | US$285.61m |
| Coste de los ingresos | US$172.97m |
| Beneficio bruto | US$112.64m |
| Otros gastos | US$466.50m |
| Beneficios | -US$353.86m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.79 |
| Margen bruto | 39.44% |
| Margen de beneficio neto | -123.90% |
| Ratio deuda/patrimonio | 0.1% |
¿Cómo se ha desempeñado IOVA a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/14 03:47 |
| Precio de las acciones al final del día | 2026/06/12 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Iovance Biotherapeutics, Inc. está cubierta por 20 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Colleen Kusy | Baird |
| Madhu Kumar | Baird |
| Peter Lawson | Barclays |